NCT04133311View on ClinicalTrials.gov

A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

386

Participants

Timeline

Start Date

April 10, 2019

Primary Completion Date

February 3, 2022

Study Completion Date

October 26, 2022

Conditions
Open-Angle Glaucoma or Ocular HypertensionOcular Surface Disease
Interventions
DRUG

DE-130A

Latanoprost 50 microg/ml eye drops emulsion, preservative-free eye drops emulsion in single-dose containers.

DRUG

Xalatan®

Latanoprost 50 microg/ml eye drops solution, eye drops in 2.5 ml dropper containers.

DRUG

DE-130A/DE-130A

After Week 12, received DE-130A continuously.

DRUG

Xalatan®/DE-130A

From week 12 onwards, DE-130A was continued to be administered instead of Xalatan®.

Trial Locations (1)

75012

Hôpital des XV-XX, Paris

All Listed Sponsors
lead

Santen SAS

INDUSTRY

NCT04133311 - A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter